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REVIEW
Abstract: None of the drugs currently available for chronic obstructive pulmonary disease 
(COPD) are able to reduce the progressive decline in lung function which is the hallmark of 
this disease. Smoking cessation is the only intervention that has proved effective. The current 
pharmacological treatment of COPD is symptomatic and is mainly based on bronchodilators, 
such as selective β2-adrenergic agonists (short- and long-acting), anticholinergics, theophylline, 
or a combination of these drugs. Glucocorticoids are not generally recommended for patients 
with stable mild to moderate COPD due to their lack of efﬁ  cacy, side effects, and high costs. 
However, glucocorticoids are recommended for severe COPD and frequent exacerbations of 
COPD. New pharmacological strategies for COPD need to be developed because the current 
treatment is inadequate.
Keywords: Chronic obstructive pulmonary disease, pharmacological treatment, 
bronchodilators, glucocorticoids, theophylline, antibiotics.
Introduction
The objective of pharmacological treatment of chronic obstructive pulmonary 
disease (COPD) is to prevent and control symptoms, reduce the frequency and 
severity of exacerbations, and improve general health status and exercise tolerance. 
None of the classes of drugs currently used in the treatment of COPD are able to 
modify the progressive decline in lung function which is the hallmark of this disease 
(Anthonisen et al 1994; Pauwels et al 1999; Vestbo et al 1999; Burge et al 2000). 
Smoking cessation is currently the only intervention which has been shown to reduce 
the progression of COPD (GICOPD 2001). To achieve this objective, behavioral 
therapy and pharmacological treatment such as the administration of bupropion 
(an antidepressant), and nicotine replacement therapy have proved useful (Jorenby 
et al 1999; Tashkin et al 2001). However, it is important to try to control symptoms 
of COPD with pharmacological treatment using the following general proposals 
(GICOPD 2001):
1) There should be a stepwise increase in treatment, according to the severity of 
the disease. The step-down approach used in the chronic treatment of asthma is not 
applicable to COPD.
2) Treatment needs to be chronic and maintained at the same level for long periods 
of time, unless signiﬁ  cant side effects or exacerbations occur.
3) Since individual patient response to the pharmacological treatment is variable, it 
is important to monitor pharmacological treatment closely and, if necessary, adjust 
it frequently.
Drugs currently recommended for the treatment of COPD are:
1) Bronchodilators (selective β2-agonists, anticholinergic antimuscarinic agents and 
methylxanthines);
2) glucocorticoids;
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3) other types of medication (vaccines, antibiotics, 
α1- antitrypsin augmentation therapy, mucolytic agents, 
antioxidants, immunoregulators, antitussives and 
vasodilators).
These drugs will be presented in the order in which they 
would normally be prescribed for the treatment of patients 
with COPD, based on the level of severity of the disease. 
Current knowledge on inhibitors of phosphodiesterase type 
4 (PDE4), a new class of drugs for COPD which are in the 
late phase III of clinical development (Lipworth 2005), 
will be presented. However, it must be emphasized that 
each treatment regimen needs to be patient-speciﬁ  c as the 
relationship between the severity of symptoms and the 
severity of lung function is inﬂ  uenced by other factors, such 
as the frequency and severity of exacerbations, the presence 
of complications, the presence of respiratory failure, the 
presence of other diseases, and general health status.
Treatment of stable chronic 
obstructive pulmonary disease
Bronchodilators
Bronchodilators are currently the mainstay of the treatment 
of COPD (GICOPD 2001). Bronchodilators are selective 
short-acting β2-agonists such as salbutamol, metaproterenol, 
terbutaline, bambuterol, pirbuterol, isoetharine, bitolterol 
and fenoterol or selective long-acting β2-agonists such as 
salmeterol and formoterol; anticholinergic antimuscarinic 
agents such as ipratropium bromide, oxitropium bromide 
and tiotropium bromide, and methylxanthines such as 
theophylline. Short- and long-acting β2-agonists and 
antimuscarinic agents are generally administered by 
inhalation (aerosol, dry-powder or nebuliser solution). 
Bronchodilator therapy is most frequently delivered by 
pressurized metered-dose inhalers (MDIs) or dry-powder 
inhalers (DPIs). Because of the lower bioavailability in 
asthma patients, the dose delivered by DPIs should be 
doubled compared with that of MDIs (RS 2003); while a 
study comparing ipratropium bromide delivered by MDIs 
and by DPIs in COPD patients found that there was no 
difference between these two types of inhalers (Cuvelier 
et al 2002). The use of a spacer device to improve drug 
delivery proves particularly useful for patients who have 
poor inhalation technique. In a study on patients with 
COPD, inhalation of salbutamol through MDIs with spacer 
and dry-powder inhalers produced similar bronchodilating 
effects (Ikeda et al 1999). However, further studies are 
necessary to establish deposition in the respiratory tract 
and the dose-effect relationship of drugs delivered by 
different inhalers in patients with COPD, as these are 
important factors in the choice of dosage. Short-acting 
β2-agonists such as salbutamol and terbutaline are also 
available for oral or parenteral delivery. Theophylline 
is generally administered orally, mostly frequently 
in controlled release preparations which prolong the 
pharmacological effect of the drug, even if they do not 
significantly eliminate the interindividual variability 
of the bioavailability. For chronic administration, 
bronchodilators are the mainstay of treatment of COPD as 
they prevent and improve symptoms (Chrystyn et al 1988; 
Vathenen et al 1988; Gross et al 1989; Rennard 2004). 
One of the main therapeutic effects of bronchodilators, 
at least in severe COPD, is improvement in the emptying 
of the lungs during expiration. This causes a reduction in 
dynamic hyperinﬂ  ation at rest and during exercise with 
consequent improvement in exercise tolerance (Belman 
et al 1996). However, it is not easy to predict the extent of 
this improvement based on an increase in forced expiratory 
volume in one second (FEV1) after a short period of 
bronchodilatory therapy (Berger and Smith 1988; Hay et al 
1992). The evaluation of the efﬁ  cacy of bronchodilators 
is generally based on questionnaires concerning symptom 
variation. COPD may require inhalation of a short-acting 
β2-agonist on demand or, when airways obstruction is more 
severe, chronic administration of an antimuscarinic agent 
by inhalation or a long-acting β2-agonist (RS 2003).
Selective β2-agonists
There are no signiﬁ  cant differences between the various 
β2-agonists as far as selectivity for β2-adrenoceptors is 
concerned, with the exception of metaproterenol and 
iso-etharine, which are less selective (Undem and 1 2001). 
Short-acting β2-agonists have a bronchodilatory effect within 
1 to 5 minutes and which lasts for up to 4 hours (Rennard 
2004). Long-acting inhaled β2-adrenergic agonists such as 
salmeterol and formoterol have a prolonged bronchodilatory 
effect for approximately 12 hours. Unlike salmeterol 
which has a slow onset of action, formoterol has a rapidly 
occurring bronchodilatory effect similar to that of short-
acting β2-agonists (Undem and Lichtenstein 2001; Rennard 
2004). Selective β2-agonists mainly work by stimulating 
the β2-adrenoceptors on the airway smooth muscle cells. 
The formation of the drug-receptor complex activates 
a stimulatory protein (Gs) which binds to guanosine 
triphosphate (GTP) with activation of the adenylate cyclase 
which leads to an increase in intracellular cyclic adenosine International Journal of COPD 2006:1(4) 411
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monophosphate (cAMP) levels which, in turn, activates 
a cAMP-dependant protein kinase (PKA) (Johnson and 
Coleman 1995). Activation of the latter causes myosin 
light chain kinase phosphorylation with a reduction in 
the afﬁ  nity of this enzyme for the calcium–calmodulin 
complex, a reduction in the formation of active myosin light 
chain kinase, a reduction in myosin phosphorylation and, 
ﬁ  nally, a reduction in the interaction of actin and myosin 
ﬁ  laments with consequent bronchodilation. In addition, 
PKA stimulation causes a reduction in intracellular calcium 
ion levels because of increased extrusion of calcium from 
the cell, reduction in the entry of calcium into the cell, and 
increase in the uptake of calcium by the smooth endoplasmic 
reticulum, which is the site at which calcium ions are 
deposited within the cell. 
The reduction in the concentration of intracellular 
calcium causes a reduction in the formation of the 
calcium–calmodulin complex which produces the previously 
described effects. In addition to this main bronchodilation 
mechanism of selective β2-agonists, other mechanisms 
may, in theory, contribute to reducing airway obstruction. 
Stimulation of β2-adrenoceptors also increases potassium 
channel conduction with hyperpolarization and relaxation 
of the airway smooth muscle (Kume et al 1994). This 
effect is, in part, independent from the increase in cAMP 
levels (Kume et al 1994). The activation of ß2-receptors 
on inflammatory cells such as mast cells, basophils, 
eosinophils, neutrophils and lymphocytes cause an increase 
in cAMP levels and subsequent inhibition of the release of 
inﬂ  ammatory mediators such as leukotrienes, histamine and 
cytokines (Hughes et al 1983; Barnes 1999). β2-agonists 
increase mucociliary clearance, decrease microvascular 
permeability and may inhibit phospholipase A2 with 
subsequent reduction in the synthesis of leukotrienes, 
prostaglandins and thromboxane A2, which are important 
inﬂ  ammatory mediators (Seale 1988). The importance of 
these mechanisms on the therapeutic effect of β2-agonists 
in humans, particularly in COPD, is not known.
Inhalation limits the absorption and therefore the 
systematic side effects of β2-agonists. However, only 
about 10% of the aerosol enters the respiratory tract while 
the remainder is swallowed and may be absorbed in the 
intestinal tract with consequent systemic side effects. 
Furthermore, aerosolized particles less than 1μm in diameter 
reach the alveoli and may be absorbed in the pulmonary 
capillaries. The main side effect of selective β2-agonists 
administered by inhalation at clinical doses is muscular 
tremor. However, this tends to diminish in intensity during 
prolonged treatment. This phenomenon is known as drug 
tolerance. It is not know if drug tolerance is due to the 
down regulation of the β2-adrenoceptors on the muscle 
cytoskeleton or to adaptation phenomena in the central 
nervous system. Tachycardia is uncommon in clinical doses 
of β2-agonists administered by inhalation. The absorption 
of β2-agonists may cause tachycardia by stimulating the 
cardiac β1-adrenoceptors, particularly at higher doses 
when relative selectivity for β2-adrenoceptors is lost. 
Although there are fewer cardiac β2-adrenoceptors, their 
stimulation may also contribute to tachycardia (Undem and 
Lichtenstein 2001). This type of side effect is particularly 
relevant in patients with ischemic heart disease or pre-
existing arrhythmias. In these patients, β2-agonists need 
to be administered with caution, even when inhaled. Bron-
chodilation may cause ventilation/perfusion mismatch with 
a consequent drop in the arterial partial pressure of oxygen. 
This is generally transitory and of little importance. Other 
side effects of systemically delivered β2-agonists, such as 
hypokalemia, increase in the plasma concentrations of 
glucose, lactose, and free fatty acids are much less common 
when β2-agonists are delivered by inhalation. 
Antimuscarinic drugs
Antimuscarinics are delivered in the same way as 
bronchodilators. Antimuscarinics are quaternary ammonium 
derivatives which, after inhalation, undergo <1% absorption 
from the pulmonary or gastrointestinal tract. The 
parasympathetic nervous system has a role in the regulation 
of the bronchial tone. Vagal ﬁ  bres activate nicotinic and 
M1 muscarinic receptors on the parasympathetic ganglia 
of the respiratory tract; short postganglionic ﬁ  bers release 
acetylcholine which stimulates the M3 muscarinic receptors 
on the airway smooth muscle cells with consequent 
increase in motility. In addition, the airway submucosal 
glands have M3 muscarinic receptors. M3 muscarinic 
receptor stimulation increases bronchial secretion. 
Inﬂ  ammatory mediators such as eicosanoids, histamine, 
and bradykinin may further produce parasympathetic 
reﬂ  exes which partly explains their bronchoconstriction 
effect. Antimuscarinic bronchodilators are non-selective 
antagonists of cholinergic muscarinic receptors. Their effect 
on airway obstruction is mainly due both to M3 muscarinic 
receptor antagonism in the airway smooth muscle cells, 
with consequent bronchodilation, and to M3 muscarinic 
receptor antagonism in the cells of the submucosal glands, 
with a reduction in the basal and stimulated cholinergic International Journal of COPD 2006:1(4) 412
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parasympathetic activity with consequent reduction in 
airway obstruction. Unlike atropine, antimuscarinic 
bronchodilators do not have an inhibitory effect on 
mucociliary clearance. The reason for this difference is 
not known. The effectiveness of antimuscarinic drugs 
depends on the role that cholinergic vagal tone has in the 
pathophysiology of bronchial obstruction. Antimuscarinic 
bronchodilators are generally considered to be more 
effective for COPD than for asthma. This could be partly 
due to the different pathophysiological role of the 
parasympathetic vagal system in these two diseases. The 
aerosol inhalation of ipratropium has a maximum effect 
30–60 minutes after administration; its duration of action 
is 3 to 6 hours, making administration of the drug necessary 
3 to 4 times a day. Ipratropium generally produces the same 
moderate bronchodilation as obtained with maximum doses 
of β2-agonists (Undem and Lichenstein 2001). Oxitropium 
produces similar pharmacological effects to ipratropium 
and can be administered twice a day. Tiotropium bromide, 
a new long-acting anticholinergic drug, which can be 
administered just once a day, has similar or greater 
efﬁ  cacy compared with other bronchodilators (Calverley 
2000) and is useful in combination with formoterol for 
COPD treatment (van Noord et al 2006). A randomized, 
prospective, double-blind, placebo-controlled, multicenter 
trial to assess whether adding salmeterol or salmeterol–
fluticasone to chronic therapy with tiotropium would 
provide additional clinical beneﬁ  t to patients with moderate 
to severe COPD is currently being carried out (Aaron 
et al 2004). Tiotropium improves sleeping arterial oxygen 
saturation (McNicholas et al 2004) and, in combination 
with pulmonary rehabilitation, exercise tolerance in patients 
with COPD (Casaburi et al 2005). Tiotropium bromide is 
indicated in the maintenance treatment of COPD, but it is 
not effective in relieving acute bronchospasms. However, 
as is the case with asthmatic patients, some authors raised 
doubts about chronic administration of bronchodilators 
which could be associated with worsening COPD (van 
Schayck et al 1991). Because of their negligible absorption, 
antimuscarinics rarely cause systemic side effects and are 
generally well tolerated. Possible side effects include dry 
mouth, nausea, constipation, and headache (RS 2003). 
Antimuscarinic bronchodilators should be administered 
with caution in glaucoma, benign prostatic hypertrophy 
and urinary obstruction (RS 2003; Rennard 2004). Cases 
of acute angle-closure glaucoma have been reported with 
nebulized ipratropium, particularly when given with 
nebulized salbutamol.
Theophylline
Theophylline, a methylxanthine, is one of the least 
expensive bronchodilators. Given its very low solubility 
in water, theophylline is administered intravenously as 
aminophylline. Aminophylline is a theophylline and 
ethylenediamine mixture, which is 20 times more soluble 
than theophylline alone. The bronchodilatory effect 
of theophylline is due both to relatively non-selective 
inhibition of cyclic neucleotide phosphodiesterases and 
to competitive antagonism of adenosine receptors (Barnes 
2003). At least eleven phosphodiesterase isozymes 
have been identiﬁ  ed (Soderling and Beavo 2000). The 
inhibition of phosphodiesterase isozymes type III and IV 
causes relaxation of the airway smooth muscle cells in 
vitro (Torphy et al 1993). Selective phosphodiesterase-4 
inhibitors for COPD are currently in clinical trials (Lipworth 
2005). Adenosine receptor antagonism also contributes 
to the brochodilatory effect of theophylline (Feoktistov 
et al 1998). In addition to bronchodilation, theophylline 
may have anti-inflammatory effects at lower plasma 
concentrations in the respiratory tract as shown by the 
reduction both in the number of neutrophils and in the 
interleukin-8 concentration in induced sputum from 
COPD patients, where the same effects cannot be obtained 
after inhalation of high glucocorticoid doses (Barnes 
2003). In vitro studies have shown that low doses of 
theophylline may enhance the anti-inﬂ  ammatory effect 
of corticosteroids and antagonize the “resistance” to 
corticosteroids caused by smoking in COPD patients by 
activating histone deacetylases (Barnes 2003, 2006). 
Theophylline is generally administered orally in 
conventional form or, more frequently, through sustained-
release preparations or intravenously (like aminophylline) 
(Undem and Lichtenstein 2001). Sustained-release 
preparations are available for administration every 8, 12, 
or 24 hours. Intravenous administration of theophylline 
must be given very slowly, over at least a 20 minute 
period (RS 2003), because of the risk of serious toxic 
effects such as arrhythmias and convulsions. Inhalation of 
theophylline is not effective and intramuscular injection 
is not possible because of its irritant effect at the site of 
injection. Absorption of theophylline from conventional 
formulations is fast and complete with a plasma 
concentration peak within two hours of administration. 
Absorption of theophylline from sustained-release 
preparations has a large interindividual variability, for 
this reason, dosage must be changed to suit the individual 
patient. Theophylline is mainly eliminated by hepatic International Journal of COPD 2006:1(4) 413
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metabolism (less than 15% is excreted in the urine 
unchanged) (Undem and Lichtenstein 2001). There is wide 
variation in the rate of elimination of theophylline. The 
half-life of elimination is on average 8 to 9 hours in adults 
and about 3.5 hours in children (Undem and Lichtenstein 
2001). The half-life is increased in heart or liver failure, 
viral infections, in the elderly and with concomitant 
administration of some drugs such as cimetidine, 
ciprofloxacin, erythromycin, fluvoxamine, and oral con-
traceptives. The half-life of elimination of theophylline is 
decreased in smokers and in chronic alcoholics, and with 
concomitant administration of drugs such as phenytoin, 
carbamazepine, rifampicin, and barbiturates (RS 2003). 
In addition to bronchodilation, theophylline may increase 
cardiac contractility, have a psychostimulant or diuretic 
effect, and increase diaphragmic contractility. A possible 
therapeutic importance for COPD has been attributed 
to this last effect. However, theophylline has some dis-
advantages including its low therapeutic index which 
limits its administration. For this reason, and because 
of the large interindividual variability in its bioavail-
ability, therapeutic monitoring of plasma theophylline 
concentrations is required. This involves taking regular 
blood samples after the theophylline concentrations reach 
a steady-state to ensure that the plasma theophylline 
concentration is within the therapeutic range for plasma 
theophylline concentrations for which the majority of 
patients obtain therapeutic effects without toxic effects, 
even though side effects are found with therapeutic 
concentrations. The therapeutic range for theophylline is 
between 10–20 μg/ml. Toxic side effects are associated 
with theophylline concentrations of more than 25 μg/ml. 
The risk of serious toxic effects, such as arrhythmias and 
convulsions, is high with theophylline concentrations of 
more than 40 μg/ml. At therapeutic plasma concentrations 
the main side effects of theophylline include anorexia, 
nausea, vomiting, insomnia, agitation, palpitation, and 
hypotension (Undem and Lichtenstein 2001).
Glucocorticoids
Inhaled glucocorticoids currently available include 
beclomethasone dipropionate, budesonide, ﬂ  unisolide, 
ﬂ  uticasone propionate and triamcinolone acetonide. There 
are no signiﬁ  cant differences between these drugs in terms 
of their efﬁ  cacy and tolerability (Undem and Lichtenstein 
2001; RS 2003). Mometasone and ciclesonide, two new 
glucocorticoids in advanced clinical trials, seem to have 
a longer duration of action with the possibility of once 
a day administration. Ciclesonide is a prodrug which is 
activated by a pulmonary esterase, with the possibility 
of increased selectivity of action and reduced systemic 
side effects resulting from glucocorticoid absorption. 
Glucocorticoids do not cause relaxation of the airway 
smooth muscle and therefore have no effect on acute 
bronchoconstriction. Glucocorticoids bind to specific 
cytoplasmic receptor proteins, which, in turn bind to 
regulatory proteins such as heat shock proteins and an 
immunophyllin (Undem and Lichtenstein 2001). The 
glucocorticoid–receptor interaction causes a receptor 
conformational change which leads to regulatory protein 
detachment, dimerization of the glucocorticoid receptor 
complexes and translocation to the nucleus where the 
drug-receptor complex binds to speciﬁ  c regulatory DNA 
sequences (glucocorticoid response elements, GRE), 
which modulate the expression of the adjacent genes. The 
time required for gene expression and protein synthesis 
explains the delayed effect of glucocorticoids which 
generally occurs several hours after administration. The 
anti-inﬂ  ammatory mechanisms of action of glucocorticoids 
are largely due to the inhibition of gene expression which 
encodes for proinﬂ  ammatory cytokines in the airway in-
ﬂ  ammatory cells (Undem and Lichtenstein 2001). Part of 
the anti-inﬂ  ammatory effect of glucocorticoids may be due 
to the induction of lipocortin. Lipocortin is a protein which 
inhibits phospholipase A2. Phospholipase A2 enzymes 
cause cleavage of arachidonic acid from phospholipids 
in the plasma membrane. The arachidonic acid is the 
substrate for the synthesis of leukotrienes, prostaglandins, 
and thromboxane A2, which are important inﬂ  ammatory 
mediators. Although glucocorticoids are generally effective 
in asthma, the anti-inﬂ  ammatory effect of glucocorticoids 
in COPD patients remains controversial and seems to 
be very limited (Pauwels et al 1999; Vestbo et al 1999; 
Burge et al 2000; LHSRG 2000). This seems to reﬂ  ect a 
pathophysiological difference between COPD and asthma. 
It has been suggested, on the basis of in vitro studies, 
that oxidative stress and cigarette smoke, which both 
play an important role in the pathophysiology of COPD, 
induce resistance to the action of glucocorticoids through 
mechanisms which involve the acetylation of histones. 
Histones are nucleic proteins that are important regulators 
in gene expression (Barnes 2000, 2003). Furthermore, the 
variable effects of glucocorticoids on airway inﬂ  ammation 
may be due to the heterogeneity of the disease and the 
limited reproducibility of markers of inflammation 
(Keatings et al 1997; Confalonieri et al 1998). What is International Journal of COPD 2006:1(4) 414
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certain is that glucocorticoids do not modify the natural 
history of COPD, as measured by the rate of decline 
in FEV1 (Figure 1). Four large randomized placebo-
controlled multicenter clinical trials (European Respiratory 
Society study on chronic obstructive pulmonary disease 
[EUROSCOP], Copenhagen City Lung Study, Inhaled 
Steroids in Obstructive Lung Disease in Europe [ISOLDE], 
and Lung Health Study 2 [Pauwels et al 1999; Vestbo 
et al 1999; Burge et al 2000; LHSRG 2000]) all found 
that inhaled glucocorticoids had no signiﬁ  cant effects on 
the progressive decline in FEV1 in patients with mild and 
moderate to severe COPD. One of these studies (Burge 
et al 2000) in patients with more severe COPD showed 
a reduction in the frequency of exacerbations (from 1.33 
to 0.99 per year, a reduction of 25%). Other clinical trials 
with both ﬂ  uticasone and budesonide showed that inhaled 
glucocorticoids reduce COPD exacerbation rate (Calverley, 
Pauwels, et al 2003; Jones et al 2003; Szafranski et al 
2003), although the mechanism for this effect is currently 
unknown. However, an earlier study on a smaller sample 
showed a reduction in severity, but not in the frequency of 
exacerbations with inhaled glucocorticoids (Paggiaro et al 
1998). From these clinical trials it is concluded that inhaled 
glucocorticoids should only be administered to patients with 
severe to very severe COPD (post-bronchodilator FEV1 
≤50% of the predicted value) with frequent exacerbations 
requiring treatment with antibiotics or oral glucocorticoids 
(GICOPD 2001). The dose of glucocorticoids required to 
reduce the frequency of exacerbations in these patients with 
COPD is not known (MacNee and Calverley 2003). 
Improvement in airﬂ  ow in patients with COPD after 
chronic treatment with inhaled glucocorticoids is very 
modest (Pauwels et al 1999; Burge et al 2000). However, 
some studies reported further improvement in airflow 
when glucocorticoids are added to long-acting β2-agonist 
bronchodilators (Mahler et al 2002; Calverley, Pauwels, et al 
2003; Szafranski et al 2003).
One study reported that withdrawal of fluticasone 
propionate from combined salmeterol–fluticasone 
treatment in patients with COPD resulted in acute and 
persistent deterioration in lung function and dyspnoea and 
in increase in mild exacerbations (Wouters et al 2005). 
However, median percentage predicted FEV1 at start of 
the 3 month run-in period was about 50% implying that a 
considerable number of patients included in this study had 
moderate COPD (FEV1 ≥50% of the predicted value) for 
which inhaled glucocorticoids are not indicated (GICOPD 
2001). On the other hand, all the patients in this study had 
a history of at least 2 COPD exacerbations in the last year 
treated with oral glucocorticoids and/or antibiotics which 
suggest chronic treatment with inhaled glucocorticoids 
(GICOPD 2001).
The effect of inhaled glucocorticoids on mortality for 
COPD is controversial and mainly based on retrospective 
data (Sin and Tu 2001; Soriano et al 2002; Fan et al 
2003; Suissa 2003; Sin et al 2005). Prospective studies 
assessing the effect of inhaled glucocorticoids and long-
acting β2-agonists, alone or in combination, on mortality 
in patients with COPD are in progress (Rennard 2004; 
Vestbo 2004). 
Oral glucocorticoids are not generally recommended for 
the treatment of stable COPD due to their limited therapeutic 
effects and numerous systemic side effects. 
Figure 1 Rate of decline in forced expiratory volume in one second (FEV1) after administration of placebo or inhaled glucocorticoids in four randomized controlled 
multicenter clinical trials: Copenhagen City Lung Study (CCLS), European Respiratory Society study On Chronic Obstructive Pulmonary disease (EUROSCOP), Inhaled 
Steroids in Obstructive Lung Disease (ISOLDE), and Lung Health Study 2 (LHS2). Inhaled glucocorticoids did not have a signiﬁ  cant effect on the rate of decline in FEV1 in 
any of the clinical trials. 
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Administration of inhaled glucocorticoids for 
patients with stable COPD must again be carefully 
considered because of possible side effects. Oropharyngeal 
candidiasis, due to the local immunosuppressive effect of 
glucocorticoids, is a common side effect. Oropharyngeal 
candidiasis is avoidable to a certain extent by using large 
volume spacers or rinsing the oropharynx with water after 
drug delivery. Even when delivered locally, such as by 
aerosolized inhaler, glucocorticoids may be partly absorbed 
with consequent systemic side effects due to their high 
lipid solubility. Particularly notable side effects include 
suppression of endogenous cortisol synthesis by inhibiting 
the hypothalamic–pituitary–adrenal axis, particularly at 
doses higher than 1500 μg/day (Undem and Lichtenstein 
2001); the possibility of osteoporosis even at doses of 
500 μg/day (Undem and Lichtenstein 2001); a slightly 
increased risk of glaucoma, particularly during long-term 
treatment at high doses, and of cataract (Undem and 
Lichtenstein 2001). Glucocorticoids, particularly at high 
doses, should be inhaled using a large-volume spacer which 
increases the profound deposition of the drug and reduces 
drug deposition in the oropharynx, with a consequent 
reduction in the incidence of candidiasis. However, in the 
absence of proven efﬁ  cacy and because of possible side 
effects, including systemic side effects, and high costs, 
there is no rational pharmacological basis for the use of 
inhaled glucocorticoids for all patients with stable COPD, 
and their use should be limited just to the cases previously 
described (GICOPD 2001).
Clinical considerations
The choice between β2-agonists, anticholinergic antimuscarinic 
agents, theophylline or drug combinations depends on 
individual patient response to the treatment. Pharmacological 
therapy at each stage of stable COPD according to Global 
Initiative for Chronic Obstructive Lung Disease (GOLD) 
guidelines is shown in Figure 2 (Figure 2). Bronchodilator 
combinations may improve drug efﬁ  cacy and reduce side 
effects, compared with an increase in the dosage of a single 
bronchodilator (COMBIVENT 1994). 
For patients with COPD, long-acting β2-agonists 
delivered by inhalation, such as salmeterol and formoterol, 
Figure 2 Pharmacological treatment of stable COPD based on GOLD guidelines. Adapted from GICOPD (2001). 
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if repeated exacerbations
Add long-term
oxygen if chronic
respiratory
failure
Consider surgical
treatmentsInternational Journal of COPD 2006:1(4) 416
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signiﬁ  cantly improve symptoms, exercise tolerance and 
general health status (Cazzola et al 1995; Ulrik 1995; Boyd 
et al 1997). Both β2-agonists and long-acting anticholinergics 
reduce the frequency of exacerbations in COPD (Rennard 
et al 2001; Casaburi et al 2002) although the mechanism(s) 
of this effect is currently unknown. Possible anti-
inﬂ  ammatory effects of long-acting β2-agonists (Johnson 
and Rennard 2001) might explain the reduced frequency of 
exacerbations of COPD (Mahler et al 1999; Rennard et al 
2001; Calverley, Pauwels, et al 2003). These bronchodi-
lators do not seem to cause tachyphylaxis, namely rapid 
reduction in the intensity of the pharmacological effect 
due to continued or repeated administration, and are well 
tolerated. Although bronchodilator treatment in COPD is 
generally started with a single agent, the use bronchodila-
tors in combination is suggested in the current guidelines 
as this strategy can result in improved bronchodilator 
and clinical effect (GICOPD 2001; Celli and McNee 
2004). However, the interindividual variability of the 
bronchodilating effect can be high. The efﬁ  cacy of combin-
ing either short or long-acting β2-agonists with anticholin-
ergics (COMBIVENT 1994; van Noord et al 2000, 2006), 
anticholinergics and theophylline (Bleecker and Britt 1991; 
Bellia et al 2002), and all three classes of bronchodilators is 
known (Nishimura et al 1995). A ﬁ  xed inhaled combination 
of albuterol and ipratropium is available. 
High doses of nebulized bronchodilators are still 
widely prescribed for severe COPD. The British Thoracic 
Society (BTS) guidelines on nebulizer therapy (NPG 1997) 
recommend that a respiratory physician should evaluate 
the effectiveness of nebulizer therapy. Before trying 
chronic nebulizer therapy, it is advisable to evaluate the 
efﬁ  cacy of high dose bronchodilator treatment delivered 
by metered dose inhaler (MDI) with a spacer. The 
administration of theophylline for stable COPD remains 
controversial. Theophylline causes bronchodilation in 
COPD (Murciano et al 1989; McKay et al 1993) with 
a variable effect on exercise tolerance and symptoms 
(Murciano et al 1984; Cooper et al 1987; Chrystyn 
1988; Mulloy and McNicholas 1993). Theophylline has 
a slow onset of action and it is generally recommended 
for maintenance treatment, rather than for the rapid 
treatment of symptoms. In the major guidelines for the 
treatment of COPD, theophylline is considered a third 
line bronchodilator after inhaled anticholinergics and β2 
agonists (Barnes 2006). Nevertheless, theophylline is 
a useful treatment in patients with severe COPD as its 
withdrawal leads to signiﬁ  cant clinical worsening of the 
disease (Kirsten DK 1993). The most recent and largely 
selective phosphodiesterase inhibitors, such as inhibitors 
of phosphodiesterase type 4 isoenzyme, slightly improve 
lung function in COPD (Compton et al 2001) and reduce 
the frequency of exacerbations (Edelson et al 2001; Rabe 
et al 2005; Rennard et al 2006) (see below). However, 
further studies are needed to adequately evaluate the 
efﬁ  cacy and tolerability of this new class of drugs.
Long-acting bronchodilators administered once or twice 
daily can improve symptoms to the same extent or more 
compared with chronic administration of short-acting bron-
chodilators. For this reason it is possible to consider the use 
of long-acting bronchodilators for the treatment of COPD 
patients requiring chronic treatment to improve symptoms. 
Theophylline may be recommended for patients with 
persistent symptoms instead of long-acting bronchodilator 
treatment. However, because of the disadvantages outlined 
above, administration of theophylline should be continued 
only if its efﬁ  cacy on the symptoms has been demonstrated. 
The role of theophylline in the treatment of COPD is currently 
being re-evaluated based on important pharmacological 
evidence which has allowed the molecular mechanism of 
action of theophylline to be clariﬁ  ed (Barnes 2003).
Inhaled glucocorticoids are generally prescribed for 
COPD without demonstration of their effectiveness. 
However, COPD patients generally have no, or a negligible, 
response to glucocorticoids (Pauwels et al 1999; Vestbo 
et al 1999; Burge et al 2000; LHSRG 2000; RS 2003). 
Some patients may improve after glucocorticoid treatment, 
but it is likely that these patients have concomitant asthma 
(Barnes 2000). A two-week trial of oral glucocorticoids was 
proposed to identify patients with a documented spirometric 
response, assuming that an acute response is predictive of 
a chronic response (GISCOPD 2001). However, the oral 
administration of glucocoticoids for two weeks does not 
generally allow identiﬁ  cation of those patients who will 
respond to inhaled glucocorticoids (Senderovitz et al 1999; 
Burge et al 2000, 2003). Therefore, a trial of glucocorti-
coids is not generally recommended for COPD (GISCOPD 
2001), unless required to exclude asthma (Barnes 2000). 
Glucocorticoids do not reduce airway inflammation in 
COPD (Barnes 2000) and various long-term studies showed 
that glucocorticoids are not able to reduce the progression 
of COPD (Pauwels et al 1999; Vestbo et al 1999; Burge 
et al 2000; LHSRG 2000). For this reason, and taking into 
account the risk of systemic side effects, particularly at high 
doses, glucocorticoids should not generally be administered 
for COPD (Barnes 2000), though they are recommended International Journal of COPD 2006:1(4) 417
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for the treatment of exacerbations. Furthermore, inhaled 
glucocorticoids are recommended for symptomatic COPD 
patients who have a documented spirometric response to 
these drugs or for patients with FEV1 ≤50% of the predicted 
value and frequent exacerbations (two or more per year), 
which require antibiotics or oral glucocorticoids, according 
to the GOLD guidelines (GISCOPD 2001). However, these 
recommendations are not universally agreed (Barnes 2000), 
as the effect of inhaled glucocorticoids at high doses on the 
frequency of exacerbations in patients with severe COPD 
is controversial (Paggiaro et al 1998; Burge et al 2000). 
Furthermore, the cost of glucocorticoids as well as their 
pharmacological proﬁ  le, as discussed above, does not justify 
indiscriminate administration of inhaled glucocorticoids 
in COPD. Fixed combinations of inhaled glucocorticoids 
and long-acting β2-agonists, namely ﬂ  uticasone–salmeterol 
(Dransﬁ  el and Bailey 2004) and budesonide–formoterol, 
were approved for use in COPD in the US and other countries 
based on clinical trials showing their effectiveness for health 
status and exacerbations of COPD (Calverley, Boonsawat, 
et al 2003; Calverley, Pauwels, et al 2003; Szafranski et al 
2003). However, there were conﬂ  icting results when the 
different combination therapies were compared with the 
mono-component alone (Nannini et al 2004). More studies 
to deﬁ  nitively establish the effects of combination therapy in 
a single inhaler are required, including double-dummy trials 
on the comparative effects with separate adiministration of 
the two drugs (Nannini et al 2004).
Other drugs 
Vaccines
Vaccination can reduce severe complications and 
mortality from influenza in elderly patients, including 
those with COPD. Vaccination is recommended once 
in the autumn or, once in the autumn and once in the 
winter each year (Nichol et al 1994; Hak et al 1998). 
Pneumococcal vaccines have been used in COPD patients 
and can reduce complications of pneumonia in elderly 
patients, but there is no evidence to support its general 
use in COPD patients.
Antibiotics
Numerous large-scale controlled studies have shown that 
prophylactic antibiotics and chronic antibiotic administration 
have no effect on the frequency of exacerbations in COPD 
(MacNee and Calverley 2003). Prophylactic antibiotics are 
also ineffective in winter (MacNee and Calverley 2003). 
Current available data does not support the effectiveness 
of prophylactic antibiotics against bacterial infections or 
exacerbations of COPD.
Mucolytic agents
Mucolytic agents such as ambroxol, erdosteine, carbocysteine, 
and iodinated glycerol produce a reduction in the frequency of 
exacerbations in chronic bronchitis compared with a placebo 
(Poole and Black 2000). Since these studies are of relatively 
short duration, between two to six months, and in patients 
with mild to moderate COPD (FEV1 >50% of the predicted 
value), the systematic administration of mucolytic drugs in 
COPD is not currently recommended.
Antioxidants
Oxidant stress plays an important role in the pathophysiology 
of COPD. Therefore, administration of antioxidant agents is 
an interesting treatment strategy. Although antioxidant and 
mucolytic drug N-acetylcysteine has been shown to reduce 
the frequency of exacerbations of COPD in most clinical 
trials (Grandjean et al 2000), a recent 3 year randomized 
placebo-controlled multicenter trial has shown that N-
acetylcysteine is ineffective at prevention of deterioration in 
lung function and prevention of exacerbations in patients with 
COPD (Decramer et al 2005). On the basis of current data, 
N-acetylcysteine is not recommended for COPD (MacNee 
and Calverley). The details of various antioxidants trials are 
discussed elsewhere (Rahman 2006). 
Drugs in phase III of clinical development
Phosphodiesterase-4 inhibitors
Selective inhibitors of phosphodiesterase (PDE) type 4 
increase intracellular concentrations of cyclic AMP by 
inhibiting its breakdown with consequent airway smooth 
muscle relaxation and anti-inﬂ  ammatory effects on effector 
cells involved in the pathophysiology of COPD (Lipworth 
2005). PDE4 enzymes include at least four isoenzymes 
(PDE4A, PDE4B, PDE4C, and PDE4D) (Soderling and 
Beavo 2000). Inhibition of PDE4B is mainly responsible for 
the anti-inﬂ  ammatory effects of PDE4 inhibitors, whereas 
inhibition of PDE4D causes nausea which is one of the main 
adverse effects of these drugs (Lipworth 2005). Cilomilast 
and roﬂ  umilast, the two main orally active PDE4 inhibitors, 
are in the late phase III of clinical development for COPD 
(Lipworth 2005). Placebo-controlled studies for up to 
6 months with cilomilast 15 mg twice daily and roﬂ  umilast 
500 mg once daily have shown small, although signiﬁ  cant, 
improvements in lung function tests in patients with COPD 
(Compton et al 2001; Rabe et al 2005). PDE4 inhibitors International Journal of COPD 2006:1(4) 418
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also reduce the rate of COPD exacerbations compared with 
placebo (Rabe et al 2005; Rennard et al 2006). The effect 
of PDE4 inhibitors on health status in patients with COPD 
is variable possibly due to differences in the duration of 
treatment (Compton et al 2001; Rabe et al 2005; Rennard 
et al 2006). Cilomilast at a dose of 15 mg twice daily for 
12 weeks reduces CD4+ T-lymphocyte subsets and CD68+ 
macrophages in bronchial biopsies from patients with COPD 
(Gamble et al 2003). However, whether these changes in air-
way inﬂ  ammation are related to clinical outcomes in patients 
with COPD is unknown (Lipworth 2005). The main adverse 
effects of PDE4 inhibitors are nausea, diarrhea, and abdomi-
nal pain (Lipworth 2005). Roﬂ  umilast is more tolerated than 
cilomilast as it has similar selectivity for PDE4 isoenzymes, 
whereas cilomilast is 10 times more selective for PDE4D 
than other isoenzymes (Manning et al 1999; Hatzelmann and 
Schudt 2001). Long-term studies are required to deﬁ  nitively 
establish the effects of PDE4 inhibitors on clinical outcomes, 
including lung function, exacerbation rate, and health status 
in patients with COPD.
Treatment of exacerbations of COPD
According to a recent deﬁ  nition, exacerbations of COPD 
are “a variation in symptoms above the normal day to day 
variation which causes a change in a patient’s medica-
tion” (Rodriguez-Roisin 2000). Exacerbations of COPD 
worsen general health status (Seemungal et al 1998) and 
are considerably expensive. The number of exacerbations is 
related to disease severity. Patients with moderate to severe 
COPD have one or two exacerbations per year (Seemungal 
et al 1998; Burge et al 2000). Many factors determine the 
type of treatment used and where the treatment is carried out, 
for example, in an outpatient or hospital setting.
The severity of the exacerbations is related to the severity 
of the disease. In patients with mild COPD, exacerbations 
are associated with increased breathlessness accompanied by 
cough and sputum production. They may often be managed 
out of hospital. Exacerbations of severe COPD are often 
associated with respiratory failure which may be fatal and 
require hospital admission on a general ward or intensive care 
unit. Exacerbations are caused by bacterial or viral infections 
in around 50% of cases (Monso et al 1995; Soler et al 1998; 
Seemungal et al 2000). Other factors such as air pollution 
and temperature may cause exacerbations (MacNee 2002). 
However, it is not possible to identify a cause in about one 
third of exacerbations of COPD (Connors et al 1996). One 
of the main problems is the decision to treat exacerbations of 
COPD at home or in hospital. This decision is inﬂ  uenced by 
the severity of symptoms, the severity of COPD, and whether 
hospital admission is required. Recent trials have shown that 
about 30% of patients admitted to hospital with exacerbations 
of COPD could be adequately treated at home with immediate 
or early discharge and nurse-led home care (Skwarska et al 
2000; Cotton et al 2000; Davies et al 1999, 2000). Patients 
prefer this form of treatment, which has been widely adapted 
to facilitate the discharge of those patients initially requiring 
hospitalization (Cotton et al 2000; Ojoo et al 2002). However, 
a clinical trial showed that home care did not improve the 
health of the patients whilst increasing costs compared with 
admission to hospital (Shepperd, Harwood, Gray, et al 1998; 
Shepperd, Harwood, Jenkinson, et al 1998). 
Home treatment
The algorithm shown in Figure 3, which is based on a stepwise 
therapeutic approach (Sachs 1981; ATS 1995; Siafakas et al 
1995; Celli 1996; Shepperd, Harwood, Jenkinson, et al 1998), 
may be used in the home treatment of exacerbations of COPD 
using bronchodilators, if necessary delivered by nebulizer, 
or antibiotics if symptoms indicate a bacterial infection, and 
oral glucocorticoids in moderate to severe exacerbations. The 
dose and/or frequency of bronchodilator delivery must be 
increased or bronchodilator treatment must be started if these 
drugs have not been used previously. Administration of high 
doses of antimuscarinics on demand delivered for a number 
of days using a nebulizer may be useful, even though chronic 
nebulizer treatment is not generally recommended after an 
exacerbation (GICOPD 2001). Systemic glucocorticoids 
are effective for exacerbations of COPD as they facilitate 
clinical improvement and lung function (Thompson et al 
1996; Niewoehner et al 1999; Cotton et al 2000) and are 
recommended for patients with moderate to severe exacer-
bations of COPD when the baseline FEV1 is less than 50% 
of the predicted value (GICOPD 2001). The optimum dose 
and duration of treatment is not known, but administration 
of oral prednisolone at 40mg per day for ten days is gener-
ally effective (GICOPD 2001). Nebulized budesonide is as 
effective as oral glucocorticoids in improving lung function. 
However, it is not clear whether the increased costs of 
inhaled glucocorticoids are justiﬁ  ed in all cases (Maltais 
et al 2002). Antibiotic treatment, which does not generally 
require parenteral administration, is recommended if two 
or more of the following symptoms are present: increasing 
dyspnoea, increasing sputum purulence, or increasing sputum 
volume (Anthonisen et al 1987). Antibiotics should be chosen 
which are effective against Streptococcus pneumoniae, 
Haemophilus inﬂ  uenzae, and Moraxella catarrhalis. These International Journal of COPD 2006:1(4) 419
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are the bacteria that most frequently cause exacerbations of 
COPD. However, the choice of antibiotics must be based on 
the antibiogram (GICOPD 2001).
Hospital treatment
The criteria for necessary hospital treatment, whether 
during admission to the emergency department, or during 
hospitalization, for exacerbations of COPD are described in 
the GOLD guidelines (GICOPD 2001). Hospital treatment 
is increasingly focused on the management of lung function 
and associated complications, particularly consider-
ing the increased number of early discharges (MacNee 
and Calverley 2003). Firstly, it is necessary to establish 
whether the exacerbation of COPD may be life-threaten-
ing and if this is the case the patients must be admitted to 
intensive care. The risk of mortality from exacerbations of 
COPD is connected with the level of respiratory acidosis, 
the presence of concomitant diseases, and the need for 
assisted ventilation (Connors et al 1996). In the absence 
of these characteristics, the risk of mortality is low, even 
though patients with severe COPD require hospitalization 
(GICOPD 2001). In these cases the effectiveness of home 
treatment is poor (Shepperd, Harwood, Gray, et al 1998). 
However, the results are better if home treatment follows 
a careful assessment in the emergency department and is 
combined with adequate doctor- or nurse-administered 
home care (Gravil et al 1998). Controlled oxygen therapy 
is the cornerstone of hospital treatment of exacerbations 
of COPD (GICOPD 2001). It is relatively easy to achieve 
adequate oxygenation (PaO2 > 60 mmHg or SaO2 > 90%) in 
uncomplicated exacerbations, but CO2 retention can occur 
(GICOPD 2001). β2-agonists are the main bronchodilators 
used for the treatment of exacerbations of COPD (Siafakas 
et al 1995; Celli 1996; BTS 1997). If rapid bronchodilation 
does not occur with these drugs, an antimuscarinic agent may 
be administered, even if the effectiveness of this combination 
is controversial (Fernandez et al 1994; Moayyedi et al 1995). 
The role of theophylline in the treatment of exacerbations of 
Figure 3 Algorithm for the home treatment of an exacerbation of COPD (adapted from Global Initiative for Chronic Obstructive Lung Disease. 2001. Global strategy for 
the diagnosis, management, and prevention of chronic obstructive pulmonary disease. National Institutes of Health. National Heart, Lung, and Blood Institute. Publication 
number 2701).
Start or increase treatment with bronchodilators, 
consider antibiotics 
Re-evaluate after several hours 
Resolution or improvement 
of symptoms 
No improvement 
or resolution 
Continue the treatment, 
with reduction if possible 
Oral glucocorticoids 
Re-evaluate after several hours 
Review the chronic treatment 
Worsening of symptoms 
Admission to hospitalInternational Journal of COPD 2006:1(4) 420
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COPD is also controversial (GICOPD 2001). Theophylline 
leads to modest improvements in lung function without 
gas exchange deterioration (Barbera et al 1992; Mahon 
et al 1999). Administration of intravenous theophylline 
can be considered in more severe exacerbations (GICOPD 
2001) although the available data do not support the use of 
methylxanthines for the treatment of exacerbations of COPD 
(Barr et al 2003). However, this requires close monitoring of 
the plasma concentrations to avoid the occurrence of dose-
dependent toxic effects (Lloberes et al 1988; Emerman et al 
1990; Barbera et al 1992). Oral or intravenous glucocorti-
coids are recommended with bronchodilator therapy and, if 
necessary, antibiotics and oxygen therapy, for treatment in 
hospital of exacerbations of COPD (Thompson et al 1996; 
Davies et al 1999; Niewoehner et al 1999; GICOPD 2001). 
The optimum dose of glucocorticoids is not known, but high 
doses increase the risk of signiﬁ  cant side effects. Generally 
30 mg to 40 mg of oral prednisolone is administered for 10 
to 14 days (GICOPD 2001). Prolonged treatment does not 
improve efﬁ  cacy, while increasing the risk of side effects. 
Antibiotics are only effective when exacerbations also occur 
with sputum purulence and increased sputum volume and/or 
fever, indicating a bacterial infection (Anthonisen et al 1987). 
Antibiotics must be effective against Streptococcus pneumo-
niae, Haemophilus inﬂ  uenzae, and Moraxella catarrhalis. 
These are the bacterial microorganisms most frequently 
involved in exacerbations of COPD. However, the choice of 
antibiotics must be based on the antibiogram. Toxicity due to 
excessive oxygen therapy in the emergency department is still 
a prevalent problem which could be resolved by increasing 
patient awareness of the risk (Plant et al 2000a). In cases 
of severe exacerbations of COPD (stage III) mechanical 
ventilation is required which may be invasive (conventional) 
or non-invasive with the aim of reducing morbidity and 
mortality and improving symptoms. Non-invasive positive 
pressure ventilation (NIPPV) is an effective alternative to 
conventional mechanical ventilation in the intensive care unit 
and is even applicable in the general ward with specialized 
nursing staff (Brochard et al 1995; Plant et al 2000a). NIPPV 
reduces patient morbidity and length of stay in hospital by 
preventing the onset of nosocomial pneumonia, but it is less 
effective than intermittent positive pressure ventilation in 
patients with a pH persistently <7.30 (Plant et al 2000b).
Conclusions
Pharmacological treatment of COPD is currently symp-
tomatic and is based on inhaled bronchodilators such as 
anticholinergics, selective β2-adrenergic agonists and 
theophylline. In the absence of proven efﬁ  cacy and due 
to higher costs and side effects, glucocorticoids are not 
generally recommended for stable COPD, though they 
are effective in the treatment of exacerbations. In the 
absence of drugs which reduce progressive decline in lung 
function, which is the hallmark of this disease, cessation 
of cigarette smoking, the main risk factor for COPD, is 
the most effective measure. Numerous studies are being 
carried out to deﬁ  ne the pathophysiology of COPD, about 
which still relatively little is known. It is hoped that these 
studies will allow new and effective drugs to be discovered 
and developed, as the current pharmacological treatment of 
COPD is inadequate.
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